.jpg "Patrick A. Ott, MD, PhD photo")
Clinical Director, Melanoma Center
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Dr. Patrick Ott is currently the Clinical Director of the Melanoma Disease Center at Dana Farber Cancer Institute (DFCI), serves as attending physician in the Department of Medicine at Brigham and Women’s Hospital, and has an appointment as Associate Professor at Harvard Medical School in Boston, MA. He is a clinical investigator and an integral member of the clinical trials program at Dana Farber/Harvard Cancer Center, where he designs and conducts phase 1 immunotherapy trials for patients with melanoma and a wide range of other tumors. His primary research interests are in melanoma and immunotherapy, specifically the development of innovative tumor vaccine approaches. Dr. Ott has been the Principal Investigator of a first in man clinical trial testing a personalized neoantigen vaccine (NeoVax) in patients with melanoma. The results of the study, reported in in Nature in 2017 and in Nature Medicine in 2021, established the feasibility and safety of this novel cancer vaccine approach for the first time in a coordinated clinical trial setting. Strong and consistent immunogenicity was demonstrated in patients with high risk melanoma, providing the basis for further testing of this innovative new treatment concept in other cancers. A study using an almost identical personal neoantigen vaccine in combination with nivolumab in patients with metastatic melanoma, non-small cell lung cancer, and urothelial cancer also demonstrated that robust vaccine specific responses were generated. Furthermore, complete pathologic responses and epitope spreading were associated with clinical benefit, suggesting vaccine induced anti-tumor activity (Ott et, Cell, 2020). Dr. Ott has been the Principal Investigator and co-investigator on over 30 treatment trials, including those that have been instrumental in the clinical development of the newly FDA approved drugs pembrolizumab and nivolumab for the treatment of advanced melanoma, small cell lung cancer, and many other cancers.
Thursday, March 23, 2023
9:00 AM – 9:30 AM
Disclosure information not submitted.